Newsroom

Healthcare Pharmaceutical Biotech

Stay informed with the latest in Healthcare, Pharmaceutical and Biotech press releases through our newsroom. Explore breaking updates, industry trends, and insights shaping these vital sectors—all in one place. Whether it’s innovation, regulatory changes, or breakthroughs, our newsroom keeps you connected to the stories that matter most.

All News

Mann Eye Institute Introduces Cutting-Edge miCOR Technology for Advanced Cataract Surgery
Healthcare & PharmaceuticalProduct Announcements

Mann Eye Institute Introduces Cutting-Edge miCOR Technology for Advanced Cataract Surgery

July 23, 2024 9:00 AM

HOUSTON, TX / ACCESSWIRE / July 23, 2024 / Mann Eye Institute, a leader in ophthalmologic care, proudly announces the integration of the ZEISS miCOR 700 technology into their cataract surgery procedures. This innovative lens extraction device represents the future of cataract treatment, offering enhanced precision, safety, and efficiency. The ZEISS miCOR 700 revolutionizes lens extraction by eliminating the need for ultrasound. Unlike...

Read more
Transparency Launches To Forge The Future Of Drug Safety With Portable Test Kits For Every Substance
Healthcare & PharmaceuticalCompany Update

Transparency Launches To Forge The Future Of Drug Safety With Portable Test Kits For Every Substance

July 23, 2024 9:00 AM

Transparency, a harm reduction organization providing at-home drug testing kits for any substance, today announced its official launch and formation as the parent organization of the Bunk Police. Celebrated for its strong impact in the harm reduction space, the Bunk Police provides critical education and drug testing services to enhance safety and awareness among music festival and concert attendees. Transparency builds on this strong foundation...

Read more
TIXiMED Receives IND Approval from the FDA for its Novel Oral Antidiabetic, TIX100
Healthcare & PharmaceuticalCompany Update

TIXiMED Receives IND Approval from the FDA for its Novel Oral Antidiabetic, TIX100

July 23, 2024 9:00 AM

TIXiMED, Inc. (https://tiximed.com), a clinical stage pharmaceutical company based on the breakthrough discovery that TXNIP plays an important role in the development and progression of diabetes, obtained Investigational New Drug (IND) approval from the United States Food and Drug Administration (FDA) for its oral type 1 diabetes drug, the specific TXNIP inhibitor, TIX100. This is a major milestone in the development of the company's novel...

Read more
Dr. Paul Nassif Honored in Newsweek's 2024 Ranking of America's Best Plastic Surgeons
Healthcare & PharmaceuticalCompany Update

Dr. Paul Nassif Honored in Newsweek's 2024 Ranking of America's Best Plastic Surgeons

July 23, 2024 8:45 AM

BEVERLY HILLS, CA / ACCESSWIRE / July 23, 2024 / Facial plastic and reconstructive surgeon, Dr. Paul Nassif, has been recognized in Newsweek's prestigious list of America's Best Plastic Surgeons 2024 for the second time. Dr. Nassif is known for his expertise and precision in facelift, rhinoplasty and eyelid surgery and has achieved a distinguished position among the top plastic surgeons in the country. Dr. Paul Nassif Newsweek, in collaboration...

Read more
Ainos Enrolls First Subject for Clinical Study of VELDONA-Based Animal FCGS Drug
Healthcare & PharmaceuticalCompany Update

Ainos Enrolls First Subject for Clinical Study of VELDONA-Based Animal FCGS Drug

July 23, 2024 8:30 AM

SAN DIEGO, CA / ACCESSWIRE / July 23, 2024 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused on novel AI-powered point-of-care testing ("POCT") and low-dose interferon therapeutics ("VELDONA"), today announced it has enrolled the first subject for its Taiwanese clinical study of VELDONA®-based animal drug in treating feline chronic gingivostomatitis ("FCGS"), a serious and painful chronic...

Read more
Jaguar Health Reports Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer
Healthcare & PharmaceuticalCompany Update

Jaguar Health Reports Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer

July 23, 2024 8:00 AM

SAN FRANCISCO, CA / ACCESSWIRE / July 23, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced the results from its initial analysis of the pivotal Phase 3 OnTarget trial of crofelemer for prophylaxis of diarrhea in adult cancer patients with solid tumors receiving targeted therapy with or without standard chemotherapy. Crofelemer is an FDA-approved prescription drug for the symptomatic relief of diarrhea in adult HIV/AIDS...

Read more
Ankle & Foot Surgeons Keep Patients a Step Ahead with New Advanced Techniques
Healthcare & PharmaceuticalCompany Update

Ankle & Foot Surgeons Keep Patients a Step Ahead with New Advanced Techniques

July 23, 2024 8:00 AM

The leader in podiatric care leverages industry-leading foot and ankle surgeon teams and state-of-the-art technology for patient outcomes that set new industry standards. PEACHTREE CITY, GA / ACCESSWIRE / July 23, 2024 / Renowned as a leader in podiatry for more than 40 years, Ankle & Foot Centers of America proudly announces new cutting-edge treatments for foot and ankle conditions, including bunions, plantar fasciitis, heel pain, and diabetic...

Read more
50% Imaging Error Rate in Clinical Trials Discussed by Expert Panelists from 5 NCI-Designated Cancer Centers
Healthcare & PharmaceuticalCompany Update

50% Imaging Error Rate in Clinical Trials Discussed by Expert Panelists from 5 NCI-Designated Cancer Centers

July 23, 2024 7:00 AM

Data points to a broader industry-wide imaging accuracy crisisCHICAGO, IL / ACCESSWIRE / July 23, 2024 / Yunu, a provider of medical research technology and services to life sciences companies and clinical research environments, hosted a recent panel at the Association for American Cancer Institutes' (AACI) Cancer Research Innovation (CRI) symposium that shed light on the alarming error and non-compliance rates for imaging assessments in...

Read more
David Rubenstein Joins Moderna's Board of Directors
Healthcare & PharmaceuticalCompany Update

David Rubenstein Joins Moderna's Board of Directors

July 23, 2024 7:00 AM

CAMBRIDGE, MA / ACCESSWIRE / July 23, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that David M. Rubenstein, Co-Founder and Co-Chairman of The Carlyle Group, will join Moderna's Board of Directors, effective August 5, 2024. Upon Mr. Rubenstein's appointment, directors Robert Langer and Stephen Berenson will also retire from the Board. Mr. Rubenstein will replace Mr. Berenson on the Audit Committee of the Board. Both Dr. Langer and Mr....

Read more
Relentless Health to Partner With Firefighters to Deliver PFAS Testing
Healthcare & PharmaceuticalPartnerships

Relentless Health to Partner With Firefighters to Deliver PFAS Testing

July 22, 2024 2:45 PM

Relentless Health (formerly Diagnose Early) is partnering with the Professional Firefighters Association of South Carolina (PFFASC) to deliver at-home PFAS testingMENLO PARK, CA / ACCESSWIRE / July 22, 2024 / Today, Relentless Health (formerly Diagnose Early) provided details of our key partnership with the Professional Firefighters Association of South Carolina (PFFASC). Relentless Health has worked closely with the PFFASC as we develop our...

Read more
Global On-site Preventive Care Market to advance at a 5.2% CAGR from 2024 to 2034, accumulating USD 43.52 Billion | Future Market Insights, Inc.
Healthcare & PharmaceuticalCompany Update

Global On-site Preventive Care Market to advance at a 5.2% CAGR from 2024 to 2034, accumulating USD 43.52 Billion | Future Market Insights, Inc.

July 22, 2024 11:00 AM

The global on-site preventive care market is estimated to be worth USD 26.21 billion in 2024 and is projected to be valued at USD 43.52 billion in 2034. From 2024 to 2034, the market is forecasted to rise at a 5.2% CAGR.With increasing emphasis on employee wellness, employers are increasingly investing in the health and well-being of their workforce, driving the growth of the on-site preventive care market during the forecast period.The on-site...

Read more
BMCS and Commodity Vault Enter Into The Real-World Assets Tokenization Ecosystem
Healthcare & PharmaceuticalCompany Update

BMCS and Commodity Vault Enter Into The Real-World Assets Tokenization Ecosystem

July 22, 2024 10:00 AM

WOODLAND HILLS, CA / ACCESSWIRE / July 22, 2024 / BioTech Medics, Inc. (OTC PINK:BMCS) and its subsidiary Commodity Vault are pleased to announce that the firms have created the architecture for our RWA Tokenization Trading Platform that includes, tokens, various commodities, verified blockchains, white papers, apps, wallets, websites, stocks and strategic partnerships all of these components, and more encompass our ecosystem. This year...

Read more
Bristol Myers Squibb's Commitment to Environment, Social and Governance: Our Progress & Aspirational Goals
Healthcare & PharmaceuticalEnvironmental, Social and Governance

Bristol Myers Squibb's Commitment to Environment, Social and Governance: Our Progress & Aspirational Goals

July 22, 2024 9:45 AM

NORTHAMPTON, MA / ACCESSWIRE / July 22, 2024 / Bristol Myers Squibb CompanyOur Approach to ESGAt BMS, we understand that the future of our company, employees, communities, and the planet are inextricably linked. Our passion for making an impact extends beyond the discovery, development and delivery of innovative medicines that help patients prevail over serious diseases. Through our ESG strategy, we seek to mobilize our capabilities and...

Read more
Lovemère Introduces the Smallest Ever Warming Lactation Massager to Enhance Breastfeeding and Pumping for Moms
Healthcare & PharmaceuticalCompany Update

Lovemère Introduces the Smallest Ever Warming Lactation Massager to Enhance Breastfeeding and Pumping for Moms

July 22, 2024 9:06 AM

SINGAPORE, SINGAPORE / ACCESSWIRE / July 10, 2024 / Lovemère, a prominent innovator in maternity and nursing wear, proudly announces the launch of its latest product: the Lovemère Warming Lactation Massager. Designed to offer unmatched comfort and relief, this compact device aims to improve the breastfeeding and pumping experience for mothers.The Smallest Ever, Yet Most PowerfulThe Lovemère Warming Lactation Massager distinguishes itself as the...

Read more
A Place At Home Celebrates Strong First Half of 2024 With Eight New Units
Healthcare & PharmaceuticalCompany Update

A Place At Home Celebrates Strong First Half of 2024 With Eight New Units

July 22, 2024 9:00 AM

A Place At Home, a senior-focused home care provider franchise, is entering the second half of 2024 with momentum from a strong first half. The franchise successfully added eight new units, bringing the total to 59 across the nation."Our growth is a testament to the effectiveness of our proven business model and the demand for our services," said Jason Evanich, president and co-founder of A Place At Home. "Many of our franchisees are headed for...

Read more
Omni-Biotic AB 10 Wins Product of the Year at NutraIngredients USA Awards 2024
Healthcare & PharmaceuticalAwards

Omni-Biotic AB 10 Wins Product of the Year at NutraIngredients USA Awards 2024

July 22, 2024 8:00 AM

NEW YORK, NY / ACCESSWIRE / July 22, 2024 / Omni-Biotic US is proud to announce that Omni-Biotic AB 10 has been awarded "Product of the Year" in the "Microbiome Modulation" category at this year's prestigious NutraIngredients USA Awards.Omni-Biotic AB 10 Omni-Biotic AB 10 Box and Sachet The judges highlighted Omni-Biotic AB 10's exceptional impact on gut health and its innovative approach to addressing gut dysbiosis, stating: "Supported by trial...

Read more
MIRA Pharmaceuticals Reveals Preclinical Success: Ketamir-2 Optimized for Brain Delivery, Avoiding Ketamine's Drug Resistance
Healthcare & PharmaceuticalCompany Update

MIRA Pharmaceuticals Reveals Preclinical Success: Ketamir-2 Optimized for Brain Delivery, Avoiding Ketamine's Drug Resistance

July 22, 2024 8:00 AM

MIAMI, FL / ACCESSWIRE / July 22, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a leading pre-clinical-stage pharmaceutical company, today announced new preclinical study results for its novel oral ketamine analog, Ketamir-2.The additional data announced today continues a string of promising preclinical results announced by MIRA in recent months for Ketamir-2 as MIRA works towards its goal of submitting an...

Read more
Protagonist Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2024
Healthcare & PharmaceuticalConferences

Protagonist Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2024

July 22, 2024 7:00 AM

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat and one-on-one meetings at the BTIG Virtual Biotechnology Conference.BTIG Virtual Biotechnology Conference - August 5-6, 2024Format: Fireside ChatDay/Time: Tuesday, August 6 at 2:00-2:35 P.M. EDTIf you are interested in meeting with the Protagonist...

Read more
Biotricity Announces Continued Margin Improvement Driven by its Proprietary AI Cloud
Healthcare & PharmaceuticalCompany Update

Biotricity Announces Continued Margin Improvement Driven by its Proprietary AI Cloud

July 22, 2024 7:00 AM

REDWOOD CITY, CA / ACCESSWIRE / July 22, 2024 / Biotricity Inc. (Nasdaq:BTCY), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced ongoing improvements in operational efficiency, scalability and margin performance driven by the latest enhancements to the company's proprietary AI Cloud platform.The latest version of Biotricity's AI Cloud has improved the company's tech...

Read more
Tonix Pharmaceuticals Awarded Potential 34 million dollar Contract with U.S. Department of Defense
Healthcare & PharmaceuticalCompany Update

Tonix Pharmaceuticals Awarded Potential 34 million dollar Contract with U.S. Department of Defense

July 22, 2024 4:50 AM

Tonix Pharmaceuticals CEO Dr. Seth Lederman joined Steve Darling from Proactive to share exciting news about a significant achievement for the company. Tonix Pharmaceuticals has been awarded a potential contract worth up to $34 million over five years by the Defense Threat Reduction Agency (DTRA), an agency within the U.S. Department of Defense. This contract aims to develop small molecule broad-spectrum antiviral agents for the prevention or...

Read more

Join the thousands of ACCESS Newswire customers today who are getting millions of views on their news.


Check out our flexible subscription and pay as you go pricing

and packages.

Use Code NEWS10 for 10% off  of your first purchase.


Latest Blog Posts

Visit our blogs for press release tips, media engagement

Strategies, and Product Comparisons.

Executive delivering prepared remarks from an earnings call script
By Jennifer Hammers July 9, 2026
How to write earnings call prepared remarks that land — structure, length, the safe-harbor open, non-GAAP language, and building remarks around your strategy.
IR
By Brian Balbirnie July 8, 2026
A practical earnings call preparation checklist for IR teams — the two-week runway, consensus, logistics, Q&A prep, and Reg FD-clean disclosure timing.
ACCESS Newswire guide on AI investor relations — how AI assistants read company earnings disclosures
By Jennifer Hammers July 6, 2026
AI assistants read your earnings within minutes. Learn how IR teams make disclosures AI-readable — and how the LLM Citation Score measures your visibility.
What does Meltwater cost in 2026, and what are the alternatives? Meltwater resells press release dis
By Jennifer Hammers June 22, 2026
What does Meltwater cost in 2026, and what are the alternatives? See how ACCESS Newswire compares on distribution, data, and price.
A logo for accesswire next to a logo for rack
By Jennifer Hammers June 21, 2026
Compare Muck Rack vs ACCESS Newswire on pricing, features, and alternatives. See how ACCESS Newswire adds distribution, pitching, and analytics.
A blue and white logo with a check mark next to it
By Jennifer Hammers June 19, 2026
Compare Business Wire vs ACCESS Newswire on pricing and capabilities — and how ACCESS delivers comparable reach at a fraction of the cost.
Show More




Discover the news
by Industry:


Need help with your PR Strategy?
Learn more about our
professional PR Services today:

.MEDIA PRO 
Want to get noticed
by the Media but don’t
know how? 

.TOTAL PRO

Need full support to 

Optimize your PR

Efforts?